1
Clinical Trials associated with Prostate cancer gene therapy(Symbion Health Ltd. /Medical Center Ops./)A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of FP253 in Combination With Fludarabine Phosphate
The primary objective of this study is to determine the safety and tolerability of a gene-directed enzyme prodrug therapy for prostate cancer. FP253 contains an ovine atadenovirus that expresses the E. coli enzyme purine nucleoside phosphorylase (PNP) under the control of a prostate-directed promoter. PNP converts systemically administered fludarabine (the prodrug) into 2-fluoroadenine (the active agent) at the site where FP253 has been administered (the prostate). This localized conversion is expected to provide organ-targeted chemotherapy that should reduce the systemic side effects associated with classical chemotherapy and also reduce the risk of debilitating damage to tissues surrounding the prostate.
100 Clinical Results associated with Prostate cancer gene therapy(Symbion Health Ltd. /Medical Center Ops./)
100 Translational Medicine associated with Prostate cancer gene therapy(Symbion Health Ltd. /Medical Center Ops./)
100 Patents (Medical) associated with Prostate cancer gene therapy(Symbion Health Ltd. /Medical Center Ops./)
100 Deals associated with Prostate cancer gene therapy(Symbion Health Ltd. /Medical Center Ops./)